The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early– and Late–Stage Primary Biliary Cirrhosis
Abstract
Budesonide has been discussed as a potential treatment option in primary biliary cirrhosis (PBC). Therefore, we studied the pharmacokinetics and pharmacodynamics of budesonide in patients with PBC stage I/II and stage IV. Twelve patients with early PBC stage I/II and 7 patients with PBC stage IV under continuous treatment with ursodeoxycholic acid (UDCA) were enrolled in an exploratory trial. Each patient received oral budesonide for 3 weeks at weekly increasing dosages of 3 mg once to thrice per day. Budesonide and cortisol plasma levels, urinary cortisol excretion, serum liver tests, and immunoglobulins were determined on days 1, 7, and 21 of the study. Patients with PBC stage IV showed significantly higher peak plasma concentrations (4.9 ± 3.5 vs. 1.5 ± 0.4 ng/mL; P < .05) and areas under the plasma concentration–time curves (AUC) (23.2 ± 16.8 vs. 5.1 ± 1.4 hours · ng/mL, P < .01, total AUC extrapolated to infinity [AUC 0–∞]) after a single dose of 3 mg budesonide when compared with patients with PBC stage I/II. Equally, AUC of budesonide were significantly increased under a multiple dose regimen on day 21 (14.0 ± 11.6 vs. 5.0 ± 1.9 hours · ng/mL, P < .01, AUC at steady state from dosing time to 8 hours [AUC ss,0–8 h]). Higher levels of budesonide were related to a significant decrease in plasma cortisol and reduction of urinary cortisol excretion in patients with stage IV disease. Two patients with stage IV disease developed portal vein thrombosis (PVT). In conclusion, administration of budesonide leads to markedly elevated plasma levels in cirrhotic patients with PBC associated with serious adverse drug reactions. Thus, further evaluation of combined treatment with UDCA may be considered in early–stage PBC but not in cirrhotic patients with PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448
Self-citationLeuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70351-3 · Cited by 247
Research works printed but not linked: 28
- Heathcote, 2000, Hepatology, 31, 1005, 10.1053/he.2000.5984 · DOI · Paper page
- Neuberger, 1997, Lancet, 350, 875, 10.1016/S0140-6736(97)05419-6 · DOI · Paper page
- Heathcote, 2000, Can J Gastroenterol, 14, 43, 10.1155/2000/989486 · DOI
- Leuschner, 2000, Gut, 46, 121, 10.1136/gut.46.1.121 · DOI
- Pasha, 1996, Med Clin North Am, 80, 995, 10.1016/S0025-7125(05)70477-6 · DOI
- Mitchison, 1989, Hepatology, 10, 420, 10.1002/hep.1840100405 · DOI
- Bar-Meir, 1998, Gastroenterology, 115, 835, 10.1016/S0016-5085(98)70254-9 · DOI · Paper page
- Greenberg, 1994, N Engl J Med, 331, 836, 10.1056/NEJM199409293311303 · DOI · Paper page
- Ryrfeldt, 1982, Eur J Respir Dis Suppl, 122, 86
- Jonsson, 1995, Drug Metab Dispos, 23, 137
- , , , , . Principles of topical versus systemic corticoid treatment in inflammatory bowel disease. In: , eds. Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy. Boston: Kluwer, 1996:42-60.
- Angulo, 2000, Hepatology, 31, 318, 10.1002/hep.510310209 · DOI · Paper page
- George, 1995, Hepatology, 21, 120
- Rodighiero, 1999, Clin Pharmacokinet, 37, 399, 10.2165/00003088-199937050-00004 · DOI · Paper page
- . Clinical Pharmacokinetics. Concepts and Applications. Baltimore: Williams & Wilkins, 1995:117-130.
- Steinijans, 1992, Int J Clin Pharmacol Ther Toxicol, 30, s45
- , , , , , , et al. Pharmacokinetics and pharmacodynamics of budesonide-ph-modified release capsules. In: , eds. Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy. Boston: Kluwer, 1996:107-120.
- Blendis, 2001, Pharmacol Ther, 89, 221, 10.1016/S0163-7258(01)00124-3 · DOI
- Cahill, 2001, Pharmacol Ther, 89, 273, 10.1016/S0163-7258(01)00128-0 · DOI
- Pihusch, 2002, J Hepatol, 37, 548, 10.1016/S0168-8278(02)00239-8 · DOI
- McLean, 1991, Clin Pharmacokinet, 21, 42, 10.2165/00003088-199121010-00004 · doi:10.2165/00003088-199121010-00004
- Morgan, 1995, Clin Pharmacokinet, 29, 370, 10.2165/00003088-199529050-00005 · DOI · Paper page
- Doherty, 2002, Clin Pharmacokinet, 41, 235, 10.2165/00003088-200241040-00001 · DOI · Paper page
- Schwab, 2001, Clin Pharmacokinet, 40, 723, 10.2165/00003088-200140100-00003 · DOI
- Hanauer, 1998, Gastroenterology, 115, 525, 10.1016/S0016-5085(98)70131-3 · DOI · Paper page
- Baker, 1999, Pediatrics, 103, 414, 10.1542/peds.103.2.414 · DOI · Paper page
- Nana, 1998, J Asthma, 35, 647, 10.3109/02770909809048967 · DOI
- Angulo, 2000, Am J Gastroenterol, 95, 2333, 10.1111/j.1572-0241.2000.02323.x · DOI
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationMack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology · doi:10.1002/hep.31065 · Cited by 983
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Self-citationAutoimmune hepatitis – Update 2015
Manns, M. P., Lohse, A. W., & Vergani, D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.005 · Cited by 371
Metadata
- Authors
- Hempfling, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U., & Sauerbruch, T.
- Venue
- Hepatology
- Published
- 2003-07
- Volume
- 38
- Issue
- 1
- Pages
- 196-202
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1999672624
- Cited by
- 165
- References
- 4
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4445 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.